Amazon Pharmacy adds Lilly's obesity pill with same-day delivery

Reports describe Amazon Pharmacy adding Foundayo, Eli Lilly's oral GLP-1 pill known chemically as orforglipron, with same-day delivery, and say the drug also became available through GoodRx. This story is only as reliable as its sourcing, and the source material provided here does not directly describe an Amazon Pharmacy listing, a GoodRx price, or same-day delivery terms for Foundayo. What is not yet known, based on available reporting, is the retail price Amazon or GoodRx charge for Foundayo, whether insurance is accepted through these channels, and how fast "same-day" delivery actually works in practice.

What is documented is a broader shift in how GLP-1 drugs reach patients outside a traditional pharmacy counter. Novo Nordisk launched NovoCare Pharmacy in March 2025 to sell Wegovy direct to patients for $499 a month, a price also available to eligible self-pay patients at local pharmacies.^[1] Eli Lilly countered by selling higher-dose vials of Zepbound directly to consumers starting in late February 2025, with the 7.5-milligram vial priced at $599 and the 10-milligram vial at $699 after an initial $499 first fill.^[1]

Pharmacy benefit managers have also reshaped access. CVS Caremark named Wegovy the preferred GLP-1 medicine on its largest commercial template formularies effective July 1, 2025, after negotiating what a CVS spokesperson told CNBC was a lower net price than Zepbound.^[1] Novo Nordisk separately expanded a partnership with Humana's CenterWell Pharmacy in late April 2025, under which telehealth companies Hims & Hers Health, LifeMD, and Ro prescribe Wegovy to self-pay patients while CenterWell handles fulfillment and home delivery.^[1] Together these moves show drugmakers, PBMs, and telehealth firms all competing to control how patients get GLP-1s and at what price, months before the reported Amazon and GoodRx availability of Foundayo.

Why it matters for patients

As GLP-1 drugs move into more retail and e-commerce channels, the price a patient pays can depend heavily on which pharmacy, insurer, or delivery service they use. The $499-per-month direct-pay pricing for Wegovy and the tiered $499 to $699 pricing for Zepbound vials show that manufacturers are already competing on price outside standard insurance billing.^[1] Formulary decisions, like CVS Caremark naming Wegovy preferred over Zepbound, can also determine which drug a patient's plan covers with lower out-of-pocket costs.^[1] For an oral pill like Foundayo entering retail and same-day delivery channels, patients may face a similarly fragmented landscape where price, availability, and delivery speed vary by where they fill their prescription. Because the sources here do not confirm Foundayo's price or insurance coverage on Amazon or GoodRx, patients weighing options do not yet have full visibility into how this specific channel compares with pharmacy benefit or telehealth routes already documented for injectable GLP-1s.^[1]

What happens next

Based on the documented pattern, further shifts in GLP-1 distribution are likely as PBMs, retailers, and telehealth platforms continue to compete for patient volume. CVS Caremark's preferred-formulary change took effect July 1, 2025, and Novo Nordisk's CenterWell partnership expanded that same month, showing how quickly these arrangements can change.^[1] Whether Amazon Pharmacy's reported same-day delivery of Foundayo and its GoodRx listing include comparable pricing or insurance terms is not yet known from available sourcing, and patients seeking that information may need to check directly with those platforms.